Neurovalens Ltd.

DUBLIN--( BUSINESS WIRE )--The "Neurostimulation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive study of the global market for neurostimulation technologies and devices. It provides a detailed description of the different types of neurostimulation technologies and devices (invasive and noninvasive) and their current and historical market revenues. The human nervous system works as the chief commander of the human body. The medical science community has long believed that it has huge potential in treatment of human body disorders. Neurostimulation technology involves the alteration or modulation of nerves. Neurostimulation devices deliver electrical current or magnetic impulses directly to nerves in order to modify their activity. Over the past 25 to 30 years, neurostimulation has emerged as one of the most dynamic fields of therapy, and has been actively investigated for treatment of a range of clinical conditions including chronic pain, movement disorders (Parkinson's disease, tremor, dystonia and others), epilepsy, psychiatric disorders, functional restoration, cardiovascular disorders, gastrointestinal disorders and genitourinary disorders. It is also said to consist of "drug-free solutions." Currently, the potential of neurostimulation technology is actively being explored for other clinical conditions including obesity, tinnitus and central nerve system disorders. Given the vast size of the potential treatment population and the many ongoing scientific discoveries and technological advances in neurostimulation technologies, the market for neurostimulation devices market is poised for significant growth. Other factors expected to aid in the market boom include many countries' growing elderly populations and increasing trends toward the use of nondrug therapies, greater expectations for quality of life, and improved patient attitudes toward receiving medical attention. Neurostimulation technologies represent a cutting-edge field in neuroscience and medical science, aiming to modulate the activity of the nervous system to treat a wide range of neurological and neuropsychiatric disorders. These innovative techniques involve the application of electrical, magnetic or optogenetic stimuli to specific areas of the brain or nervous system, offering the potential to alleviate symptoms, restore lost function and enhance cognitive capabilities. Neurostimulation is based on the concept of neuromodulation, where electrical signals are applied to neurons to alter their activity and influence neural networks. Neurons communicate through electrical impulses, and by selectively stimulating or inhibiting specific neural populations, neuroscientists and clinicians can modulate brain function. This report also covers in detail the therapeutic applications of neurostimulation technologies and devices, including chronic pain, Parkinson's disease, epilepsy, urinary and fecal incontinence, obstructive sleep apnea, essential tremor, obsessive compulsive disorder, major depressive disorder/clinical depression and others. An in-depth analysis of the global market for neurostimulation technologies and devices includes historical data and market projections by device type, therapeutic application and region. Report Includes Estimation of the market size and analyses of market trends, with data from 2020 to 2022, estimates for 2023 and projection of CAGR through 2028 Description of Dorsal Root Ganglion (DRG) neurostimulator system and discussion on approved indications of stimulation therapy for various diseases Detailed description of various types of stimulation such as spinal cord stimulation, transcutaneous electrical nerve stimulation, deep brain stimulation, sacral nerve stimulation, Vagus nerve stimulation, hypoglossal nerve stimulation, and transcranial magnetic stimulation; and discussion on their mode of action and advantages Information on recent therapy improvements and new indications for use, and discussion on alternatives to traditional stimulation therapies Coverage of ongoing scientific discoveries and technological advances in neurostimulation technologies and insights into marketed and pipeline (R&D) products, product recalls and reimbursement policies Market share analysis of neurostimulation devices by application, type and region, and evaluation of market size and forecast, and detailed analysis of drivers, challenges and opportunities affecting market growth Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies Comprehensive company profiles of major players Axonics Inc Boston Scientific Corp Medtronic PLC Synapse Biomedical Inc Xavant Technology Key Attributes: Report Attribute Details No. of Pages 160 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $8.2 Billion Forecasted Market Value (USD) by 2028 $11.7 Billion Compound Annual Growth Rate 7.4% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Overview of Neurostimulation Types of Neurostimulation Technologies Spinal Cord Stimulation Deep Brain Stimulation Sacral Nerve Stimulation (Sns) Vagus Nerve Stimulation Hypoglossal Nerve Stimulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation (Tms) Other Neurostimulation Technologies Therapeutic Applications for Neurostimulation Chronic Pain Management Neurological Disorders Urinary and Fecal Incontinence Obstructive Sleep Apnea Chronic Migraine and Headache Cardiovascular Diseases Gastrointestinal Disorders Obesity Psychiatric Disorders Technological Developments Mri Compatibility Rechargeable and Non-Rechargeable Devices Chapter 4 Market Dynamics Market Trends Drivers Market Restraints Chapter 5 Market Breakdown by Technology/Device Type Global Market for Neurostimulation Devices by Type Spinal Cord Stimulation (Scs) Devices Transcutaneous Electrical Nerve Stimulation (Tens) Devices Deep Brain Stimulation (Dbs) Devices Sacral Nerve Stimulation (Sns) Devices Vagus Nerve Stimulation (Vns) Devices Hypoglossal Nerve Stimulation (Hgns) Devices Market Size and Forecast Transcranial Magnetic Stimulation (Tms) Devices Other Types of Neurostimulation Devices Chapter 6 Market Breakdown by Therapeutic Application Global Market for Neurostimulation Devices by Therapeutic Application Chronic Pain Urinary and Fecal Incontinence Parkinson's Disease Epilepsy Obstructive Sleep Apnea (Osa) Essential Tremor Major Depressive Disorder (Mdd)/Clinical Depression Obsessive Compulsive Disorder (Ocd) Other Therapeutic Applications Chapter 7 Market Breakdown by Region Global Market for Neurostimulation Devices by Region North America Europe Asia-Pacific Rest of the World Chapter 8 Regulatory Structure Regulatory Framework U.S. European Union Japan Chapter 9 Key Products and Technologies on the Market Recent Therapeutic Improvements and New Indications Spinal Cord Stimulation Deep Brain Stimulation Sacral Nerve Stimulation (Sns) Axonics Medtronic Vagus Nerve Stimulation Hypoglossal Nerve Stimulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation Other Types of Stimulation New Indications and Neurostimulation Therapies Chapter 10 Emerging Technologies and Developments Emerging Technologies and Developments Closed-Loop Neurostimulation Non-Invasive Brain Stimulation Techniques High-Frequency Stimulation Magnetic Resonance-Guided Focused Ultrasound Optogenetics Bioelectronic Medicine Wireless and Remote-Controlled Devices Chapter 11 Recent M&A M&A in the Neurostimulation Technologies Industry Chapter 12 Competitive Landscape Company Market Shares by Product Segment Spinal Cord Stimulation Devices Deep Brain Stimulation Devices Sacral Nerve Stimulation Devices Vagus Nerve Stimulation Devices Hypoglossal Nerve Stimulation Devices Transcranial Magnetic Stimulation Devices Transcutaneous Electrical Nerve Stimulation Devices Recent Industry Activities Chapter 13 Company Profiles Abbott Laboratories Aleva Neurotherapeutics Sa Avery Biomedical Devices Inc. Axonics Inc. Bioinduction Ltd. Bioventus LLC Biowave Corp. Boston Scientific Corp. Brainsway Ltd. Cochlear Americas Cvrx Inc. Electrocore Inc. Inspire Medical Systems Inc. Integer Holdings Corp. Laborie Inc. Livanova plc Mag & More GmbH Magstim Inc. Medtronic plc Nalu Medical Inc. Neuromed Consulting Inc. Neurometrix Inc. Neuronetics Inc. Neuropace Inc. Neurosigma Inc. Neurovalens Ltd. Nevro Corp. Nexstim plc Nyxoah Sa Soterix Medical Inc. Synapse Biomedical Inc. Xavant Technology (Pty) Ltd. Zoll Medical Corp. For more information about this report visit https://www.researchandmarkets.com/r/7hblrg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The Modius Sleep device is a headset that delivers small electrical pulses through an electrode placed behind the ear, with an aim of stimulating the areas of the brain’s hypothalamus associated with the sleep-wake cycle and the circadian rhythm. People suffering from chronic insomnia now have a new, drug-free option to treat the condition in the U.S. The FDA doled out a clearance to Neurovalens’ Modius Sleep device, which relies on neuromodulation technology to target the neurological processes that cause insomnia. With the regulatory nod, the Northern Ireland-based company will now be able to focus on growing its stateside presence, CEO Jason McKeown, Ph.D., said in a company announcement. “Most other products on the market measure symptoms of insomnia, but Modius Sleep is a non-invasive device that actually treats the underlying issue, improving the lives of our patients,” McKeown continued. “We believe that the low-risk, non-invasive therapeutic intervention offered by Neurovalens technology will be truly transformative for a range of serious medical conditions and, having carried out extensive clinical trials in the U.S. and Northern Ireland, we’re really excited to be moving to this next stage.” The Modius Sleep device is a headset that delivers small electrical pulses through an electrode placed behind the ear, with an aim of stimulating the areas of the brain’s hypothalamus associated with the sleep-wake cycle and the circadian rhythm. According to Neurovalens, users should wear the headset for a 30-minute session before bed, during which they’re free to watch TV, read or do other activities as they wind down for the night. The device’s neurostimulation is meant to improve both the quality and duration of sleep. In a pilot study (PDF) of the technology in 2020, 20 adults were tasked with using the neurostimulation headset every night before bed for two weeks. By the end of the study period, they reported significant decreases in their Insomnia Severity Index (ISI) scores, as well as an improvement in how well-rested they felt throughout the day. Specifically, the participants kicked off the study with an average baseline ISI score of 15.7, indicating “moderate insomnia” on the 28-point scale, and after two weeks their average score had dropped to 8.15, well below the threshold for a clinical diagnosis of insomnia. Meanwhile, when asked to rate their restfulness on a scale of zero to four, the participants’ scores improved from an average of 1.6 before the study started to 2.67 after undergoing the two weeks of regular Modius Sleep treatment. Neurovalens’ FDA submission was supported by the results of a “robust” pivotal clinical trial conducted in the U.K., Ireland and Hong Kong, the results of which haven’t yet been published. Next up on the company’s agenda is a plan to work with insurance providers to secure reimbursement for U.S. users of the Modius sleep device. In the meantime, Neurovalens is also in the process of adapting its neurostimulation technology to a variety of other indications, including Type 2 diabetes, obesity, anxiety and post-traumatic stress disorder, the last of which is on deck to be studied in a now-recruiting clinical trial.

DUBLIN--( BUSINESS WIRE )--The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering. The neuromodulation global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029 due to increasing incidence of chronic pain, increasing parkinson's and alzheimer's disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, neurological diseases, gastroenterology, respiratory related diseases and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects. Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029. Invasive neuromodulation devices market is segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others include Gastric Electric Stimulation (GES), Respiratory Electrical Stimulation (RES) or Phrenic Nerve Stimulation (PNS). Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029 due to increase in the incidence of chronic pain, increase in movement disorders and high implantation rate of spinal cord stimulators. The Hypoglossal Nerve Stimulator segment is expected to grow at a high double digit CAGR from 2022 to 2029. The non-invasive neuromodulation devices market is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), Neuromuscular Electrical Stimulation (NMES) and others. Among these, Transcutaneous Electrical Nerve Stimulator (TENS) segment is the largest and fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other applications include Obesity, Heart Failure, Autoimmune diseases (rheumatoid arthritis), respiratory related diseases (diaphragm pacing), Diabetes and Weaning. Among these, pain management segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Obstructive Sleep Apnea segment is expected to grow at a high double digit CAGR from 2022 to 2029. Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among these, chronic pain segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029 due to increasing incidence of chronic pain, increasing utilizing of the spinal cord stimulators and advancement in neuromodulation devices. Central Nervous System is further segmented into Parkinson's disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis. Among these, Parkinson's disease segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Epilepsy segment is expected to grow at a high double digit CAGR from 2022 to 2029. Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among these, Urinary Incontinence segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029. Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among these, Hospitals and Ambulatory Surgery Centers is the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. North America accounted for the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices. Asia-Pacific is the fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at a high double digit CAGR from 2022 to 2029 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market. The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the major players in Neuromodulation devices market include Abbott Laboratories (U.S.) Axonics Inc. (U.S.) Bioventus (Bioness Inc.) (U.S.) Boston Scientific Corporation (U.S.) Inspire Medical System Inc. (U.S.) Laborie Medical (Canada) LivaNova Plc (U.K.) Medtronic Plc (Ireland) NeuroPace Inc. (U.S.) Nevro Corporation (U.S.) Factors Influencing Market Drivers and Opportunities Growing Prevalence of Treatment Resistant Chronic Conditions to Fuel the Demand for Neuromodulation Devices Growing Prevalence of Parkinson's, Alzheimer's Diseases, Neurological and Respiratory Conditions to Drive the Market Low Approval Rate of Cns Drugs is Driving Neuromodulation Market Favorable Reimbursement Scenario in Major Markets The Emergence of Neuromodulation as Add-On Therapy Technological Ainnovations in Neuromodulation Expansion in Emerging Markets the Rise in the Number of Clinical Studies Performed Restraints and Threats Side Effects and Risk Associated With the Use Lack of Trained Professionals Availability of Alternative Treatments Stringent Regulatory Guidelines Regulatory Affairs International Organization for Standardization Iso 9001: 2015 Quality Management System Iso 13485 Medical Devices Iso 10993 Biological Evaluation of Medical Devices U.S. Canada Europe Japan China India Technological Advancements Rechargeable Systems Optogenetic Technology Focused Ultrasound (Fus) Miniaturization Portable Nueromodulation Systems (Pons) Wearable Pain Management Technology Trans-Spinal Direct Current Stimulation (Tsdcs) Nano-Neuromodulation Bioactive Coatings Occipital Nerve Stimulation (Ons) Cranial Electrotherapy Stimulation (Ces) Companies Mentioned Abbott Laboratories Algostim Ates Medica Device Srl Atrotech Oy Attune Neurosciences Auri- Stim Medical, Inc Avery Biomedical Devices Inc. Axilum Robotics AxioBionics LLC Axonics Inc. Baldoni Neuromodulation Beijing Pins Medical Co., Ltd. Biocontrol Medical Bioinduction Ltd. Bioness Inc. Bioventus Inc. (Bioness Inc.,) BioWave BlueWind Medical Boston Scientific Corporation Bottneuro Brainsway Ltd. Cafely Cala Health Cardia Care Cochlear Ltd Comphya Cortec GmbH Corveus Medical CVRx Cyberonics, Inc. Cymedica Orthopedics Desyncra Technologies Djo Global (Colfax Corp.) Dw Healthcare (Cefaly Technology) DyAnsys EB Neuro S.P.A. electroCore eNeura Inc. Epineuron Technologies, Inc. Gimer Medical Greatbatch Medical G-Therapeutics Helius Medical Technologies Heuro Canada InnoCon Medical Innovative Health Solutions. Insai Inspire Medical Systems IntraPace JumpStart Inc Laborie Medical Technologies Inc. (Cogentix Medical) Livanova Plc (Sorin Group) Magnus Medical Magstim TMS Magventure A/S Mainstay Medical Medtronic Plc MetaCure, Ltd MicroTransponder Inc. Nalu Medical NDI Medical NeoSync Nesos Neuralace Medical NeurAxis Neurocare Group GMBH Neuroelectrics NeuroEm Therapeutics Inc. Neurolief Ltd. NeuroMetrix Neuronetics Neuropace Inc. Neuros Medical, Inc. Neurosigma Inc Neurovalens Nevro Corporation Nexstim Plc Northstar Neuroscience Nuraleve Inc Nuvectra Corporation Nyxoah SA ODstock Medical Olympic Ophthamalic Inc. Onward Medical Pathmaker Neurosystems Inc. Phagenesis Precidio Medical Precisis AG Pulvinar Neuro (Electromedical Products International, Inc (EPI)) REMED Co., Ltd. Rogue research Saluda Medical Salvia Bioelectronics Sana Health SceneRay Technologies Set Point Medical ShiraTronics Signifier Medical Technologies Ltd Sooma Oy Soterix Medical Spark Biomedical SPR Therapeutics Stimdia Medical Inc, Stimwave LLC Sublimed Synapse Biomedical Inc. Syneika Theranica Bio-Electronics Ltd. tVNS Technologies Uroplasty, Inc. Vertis Neurosciences Ybrain, INC ZOLL Medical Corporation (Respicardia, Inc.) Zosano Zynex Medical, Inc. For more information about this report visit https://www.researchandmarkets.com/r/cjnxze